89 patents currently held
9 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Oct 2028. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Oct 2028
Next term end
43
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2034 · High confidence
Also notable
Ends Apr 2033 · High confidence
Also notable
Ends Jan 2036 · High confidence
Quinoline Derivative
US 9,573,935
The most cited patent in this portfolio, cited by 17 later US patents, top 25% of utility patents granted in 2017 in our data. Protection runs to 2034.
Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content
US 9,981,002
The largest patent family in this portfolio, 8 related applications, renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Tricyclic Spiro Compound
US 10,077,247
The largest patent family in this portfolio, 5 related applications, renewed at every maintenance window due so far. Protection runs to 2036.
Formerly held, still cited
Notable
Ends Jun 2027 · High confidence
Cited by 298 later US patents, top 1% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
now held by E. R. Squibb & Sons, L.L.C.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 4, 2027The maintenance fee for Compound Having KDM5 Inhibitory Activity and Pharmaceutical Use Thereof (US 11,691,968) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 2 fees due Feb 6 to 13, 2027 · next Feb 6
- 1 fee due Mar 10, 2027The maintenance fee for Dihydroindolizinone Derivative (US 10,407,426) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
- 2 fees due Apr 1 to 6, 2027 · next Apr 1
- 2 fees due May 26 to 28, 2027 · next May 26
- 3 fees due Jun 1 to 26, 2027 · next Jun 1
- 1 fee due Jul 21, 2027The maintenance fee for Tricyclic Spiro Compound (US 10,538,502) comes due Jul 21, 2027. Unpaid by Jan 21, 2028, it lapses early.
- 2 fees due Aug 4 to 13, 2027 · next Aug 4
- 3 fees due Sep 3 to 5, 2027 · next Sep 3
- 3 fees due Nov 12 to 14, 2027 · next Nov 12
Recent changes
- 4 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 43 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Purinone Derivative Hydrochloride | 8 in force | to Nov 2032 |
| Bicyclic Compound and Use Thereof for Medical Purposes | 8 in force | to Aug 2030 |
| Methods of Producing Anamorelin Hydrochloride Having Controlled Chloride Content | 7 in force | to Apr 2033 |
| Purinone Derivative | 6 in force | to May 2031 |
| Quinoline Derivative | 5 in force | to Jul 2034 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,964,726 | Tricyclic Compound and Use Thereof In force · High confidence | In force | High confidence | |
| US 8,216,996 | Multimer of Extracellular Domain of Cell Surface Functional Molecule In force · High confidence | In force | High confidence | |
| US 8,614,340 | Bicyclic Compound and Use Thereof for Medical Purposes In force · High confidence | In force | High confidence | |
| US 8,962,868 | Bicyclic Compound and Use Thereof for Medical Purposes In force · High confidence | In force | High confidence | |
| US 9,029,574 | Bicyclic Compound and Use Thereof for Medical Purposes In force · Medium confidence | In force | Medium confidence | |
| US 9,388,157 | Bicyclic Compound and Use Thereof for Medical Purposes In force · High confidence | In force | High confidence | |
| US 9,889,114 | Bicyclic Compound and Use Thereof for Medical Purposes In force · High confidence | In force | High confidence | |
| US 10,201,520 | Bicyclic Compound and Use Thereof for Medical Purposes In force · Medium confidence | In force | Medium confidence | |
| US 10,940,134 | Bicyclic Compound and Use Thereof for Medical Purposes In force · Medium confidence | In force | Medium confidence | |
| US 11,617,733 | Bicyclic Compound and Use Thereof for Medical Purposes In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 89: 9 patents in force now held by others · 203 patents ended · 39 applications pending · 158 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.